Corcept Therapeutics Incorporated - Common Stock (CORT)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Mar 26, 2026Investment Snapshot
- Trading 222% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 4/9 — moderate financial health
- ROE of 18.9% — good return on equity
- Revenue growing at 13% annually
Corcept Therapeutics Incorporated - Common Stock (CORT) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $4.3 billion . Key value metrics: P/E ratio 35.1, P/B ratio 6.65, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Corcept Therapeutics Incorporated - Common Stock — Fundamental Analysis Summary
Corcept Therapeutics Incorporated - Common Stock (CORT) is currently trading 222% above its Graham Number of $12.57, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 35.1x.
On financial health, CORT shows a moderate Piotroski F-Score of 4/9, and solid return on equity of 18.9% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.29.
StockPik's composite Value Score for CORT is 35/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CORT reports a high gross margin of 98.6% (sector average: 33.5%) and a solid operating margin of 11.7%.
CORT shows revenue growing at 13% year-over-year, with earnings declining at 29%.